PHR Phreesia, Inc.
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management u…
Industry Peers
Health Information Services| Headline | Source | Time |
|---|---|---|
Older | ||
 Wall Street Splits on Phreesia (PHR) as Margins Improve but Growth Visibility Fades On September 2, 2026, Phreesia, Inc. (NYSE:PHR) reported second-quarter fiscal 2027 results for the period ended July 31, 2026. Revenue rose 10% to $129.5 million and adjusted EBITDA climbed to $32.9 million from $22.1 million a year earlier, a 25% margin. Net income reached $1.9 million, marking the company’s fifth consecutive quarter of profitability. Management […] | ||
 Phreesia’s (PHR) Profit Turnaround Meets A Cash-Strapped Client Base On September 2, Phreesia (NYSE:PHR) reported second-quarter fiscal 2027 results for the period ended July 31, showing revenue climbing to $129.5 million and adjusted EBITDA surging to $32.9 million. The healthcare technology company posted its fifth straight quarter of positive net income and its ninth straight quarter of positive operating cash flow, even as management […] | ||
 Phreesia (PHR) Q2 2027 Earnings Call Transcript Revenue climbed to $129.5M as adjusted EBITDA surged to $32.9M. | ||
 Why Phreesia Stock Got Knocked Down Today An analyst's recommendation downgrade did the company few favors. | ||
 Why Phreesia Stock Tumbled Today Its latest quarterly earnings were not greeted warmly by Mr. Market. | ||
 Phreesia, Inc. Q2 2027 Earnings Call Summary Moby summary of Phreesia, Inc.'s Q2 2027 earnings call | ||
Phreesia Inc (PHR) (Q2 2027) Earnings Call Highlights: Record EBITDA Margin and Strategic ... Phreesia Inc (PHR) delivers 10% revenue growth and 25% adjusted EBITDA margin while expanding AccessOne and AI-driven Network Solutions. | ||
 Phreesia Q2 Earnings Call Highlights Phreesia (NYSE:PHR) reported second-quarter fiscal 2027 revenue growth and continued profitability expansion, while maintaining its full-year revenue and adjusted EBITDA outlook. The company said it generated positive operating and free cash flow for the ninth consecutive quarter and used its cash g | ||
 Phreesia (PHR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Phreesia (PHR) give insight into how the company performed in the quarter ended July 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. | ||
 Phreesia (PHR) Q2 Earnings and Revenues Lag Estimates Phreesia (PHR) delivered earnings and revenue surprises of -72.73% and -0.13%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates Veeva (VEEV) delivered earnings and revenue surprises of +5.86% and +2.64%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of -100.00% and -54.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates ADC Therapeutics (ADCT) delivered earnings and revenue surprises of +42.11% and -4.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates Enovis (ENOV) delivered earnings and revenue surprises of +8.43% and +0.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates Schrodinger (SDGR) delivered earnings and revenue surprises of +113.33% and +15.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Should Value Investors Buy Phreesia (PHR) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. | ||